Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001239681 | SCV001412573 | likely benign | Alpha thalassemia-X-linked intellectual disability syndrome | 2024-01-25 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002563952 | SCV003603485 | uncertain significance | Inborn genetic diseases | 2022-01-27 | criteria provided, single submitter | clinical testing | The c.35A>G (p.N12S) alteration is located in exon 2 (coding exon 2) of the ATRX gene. This alteration results from a A to G substitution at nucleotide position 35, causing the asparagine (N) at amino acid position 12 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Ce |
RCV004809542 | SCV005436525 | likely benign | not provided | 2024-09-01 | criteria provided, single submitter | clinical testing | ATRX: PP2, BS2 |